Survodutide
Also known as BI 456906
A dual GLP-1/glucagon receptor agonist being developed for obesity and metabolic dysfunction-associated fatty liver disease (MASH). Phase 2 showed 83% MASH resolution vs 18% placebo.
Regulatory Pathway
Dosing Protocol
Typical Dose
Research protocols only
Frequency
Weekly injection
Duration
Long-term use expected
Timing & Administration
Administer via Subcutaneous injection weekly. Frequency: Weekly injection.
Popular Uses
Mechanism of Action
Activates both GLP-1 receptors (appetite suppression, glucose control) and glucagon receptors (increased energy expenditure, reduced liver fat). Glucagon component provides additional metabolic benefits beyond standard GLP-1 agonists.
Research Summary
Evidence level: clinical trials. Clinical status: Phase 3 Clinical Trials - FDA Breakthrough Therapy Designation for MASH.
Side Effects & Safety
Important Warnings
- Phase 3 obesity trials expected completion early 2026
References
No references available.
Related Peptides
Browse all →A GLP-1 receptor agonist with multiple FDA approvals including weight management, type 2 diabetes treatment, cardiovascular risk reduction, and kidney disease protection. 94% amino acid similarity to human GLP-1.
View profileA dual GIP/GLP-1 receptor agonist representing next-generation incretin-based therapy, demonstrating superior weight loss outcomes compared to semaglutide in direct clinical comparisons.
View profileA triple agonist activating GLP-1, GIP, and glucagon receptors for enhanced weight loss outcomes.
View profile